1. Volume 145, Issue 3, Pages 574-582.e1 (September 2013)
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease 
Sunder Mudaliar, Robert R. Henry, Arun J. Sanyal, Linda Morrow, Hanns–Ulrich Marschall, Mark Kipnes, Luciano Adorini, Cathi I. Sciacca, Paul Clopton, Erin Castelloe, Paul Dillon, Mark Pruzanski, David Shapiro 
Gastroenterology 
Volume 145, Issue 3, Pages e1 (September 2013)
DOI: /j.gastro
Copyright © 2013 AGA Institute Terms and Conditions

2. Figure 1
Increased FGF19 and decreased C4 and endogenous bile acid plasma levels and weight in patients with diabetes and NAFLD after treatment with OCA. Data are presented as mean ± SEM. ∗P < .05, ∗∗P < .01, ∗∗∗P < Statistical significance is based on comparisons of absolute change from baseline between the OCA treatment groups and placebo.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions

3. Supplementary Figure 1
Disposition of patients with type 2 diabetes mellitus and NAFLD in the study.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions